• Activity INFORMATION

  Overview

  In 2022, a total of 37 novel drugs were approved by the FDA. New approvals have the potential to change the landscape for disease state management or simply become another choice in the arsenal of options. Either way, it is essential that the healthcare provider understand the new indications, adverse effects, and potential interactions and risks associated with these new players. In this session, newly approved drugs, ranging in specialties from multiple sclerosis to diabetes to carcinomas and beyond are examined from the lens of a pharmacist. The session will focus on notable approvals expected to impact pharmacy practice most significantly, while providing an overview of drugs approvals for more rare diseases as well.
  

  Handouts

  • Slide Document :   23070H01_2pp.pdf Download

  • Slide Document :   23070H01_6pp.pdf Download

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  List new drugs approved by the FDA in 2022. For each drug, the participant will be able to describe the approved indication, common adverse effects, and drug interactions.

  Analyze important drug alerts and their relevance to drug therapies.

  Pharmacy Technician

  List new drugs approved by the FDA in 2022. For each drug, the participant will be able to describe the approved indication, common adverse effects, and drug interactions.

  Analyze important drug alerts and their relevance to drug therapies.

  Nurse

  Analyze important drug alerts and their relevance to drug therapies.

  List new drugs approved by the FDA in 2022. For each drug, the participant will be able to describe the approved indication, common adverse effects, and drug interactions.

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-1092730

  Universal Activity Number

  Pharmacist 0798-0000-23-070-H01-P
  Pharmacy Technician 0798-0000-23-070-H01-T
  Nurse 0798-0000-23-070-H01-N
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Mary Lynn  McPherson, PharmD, PhD, BCPS, FAAHPM Professor and Executive Director, Advanced Post-Graduate Education in Palliative Care, University of Maryland School of Pharmacy

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).